Beneficial Effects of Selective Orexin-A Receptor Antagonist in 4-aminopyridine-induced Seizures in Male Rats

Overview

Journal Adv Biomed Res

Specialty Biomedical Engineering

Date 2018 Feb 2

PMID 29387673

Citations 2

Authors

Parichehr Hayatdavoudi

Hamid-Reza Sadeghnia

Nema Mohamadian-Roshan

Mousa Al-Reza Hadjzadeh

Affiliations

Soon will be listed here.

Abstract

Background: Orexins are excitatory neuropeptides which stimulate the central regulatory pathways. Orexins increase the penicillin-induced epileptic activity in rats. Orexin-A increases in different types of seizures and its elevated level is the characteristic feature in the epileptic children during polysomnography. Recently, the orexin receptor blockage has been reported to increase seizure threshold in mice; however, effect of the selective orexin-A receptor antagonist (SB-334867) on 4-aminopyridine (4-AP)-induced seizures has not been investigated.

Materials And Methods: We used the intraperitoneal injection of 4-AP to induce seizure in male rats. Under urethane anesthesia, SB-334867 (50 and 100 nmol) was injected stereotaxically into the ventral hippocampal commissure. Using video recording, the effects of SB-334867 on electroencephalogram and tonic-clonic convulsions were compared to those that received diazepam or dimethyl sulfoxide (DMSO).

Results: SB-334867 significantly decreased the duration of spike trains compared to DMSO-treated rats ( < 0.001) and reduced the duration of convulsive seizures ( < 0.05). Seizure onset was increased significantly by SB-334867, 50 nmol, compared to DMSO ( < 0.05) and diazepam ( < 0.01) treated rats.

Conclusion: Antagonism of orexin-A receptor by a low-dose SB-334867 showed protective effects in 4-AP-induced seizure-like activities in anesthetized rats.

Citing Articles

Can serum orexin levels be used as a marker in childhood epilepsy?.

Arslan M, Ustun C, Coskun A, Celik H, Yalcin H, Karaismailoglu E Heliyon. 2025; 11(1):e41145.

PMID: 39811283 PMC: 11729658. DOI: 10.1016/j.heliyon.2024.e41145.

Intranigral Administration of -Sitosterol--D-Glucoside Elicits Neurotoxic A1 Astrocyte Reactivity and Chronic Neuroinflammation in the Rat Substantia Nigra.

Luna-Herrera C, Martinez-Davila I, Soto-Rojas L, Flores-Martinez Y, Fernandez-Parrilla M, Ayala-Davila J J Immunol Res. 2020; 2020:5907591.

PMID: 33282962 PMC: 7685831. DOI: 10.1155/2020/5907591.

Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABA and Glutamate Receptors.

Razavi B, Farivar O, Etemad L, Hosseinzadeh H Iran J Pharm Res. 2020; 19(2):383-390.

PMID: 33224245 PMC: 7667563. DOI: 10.22037/ijpr.2019.14688.12584.

References

Rejdak K, Papuc E, Grieb P, Stelmasiak Z . Decreased cerebrospinal fluid hypocretin-1 (orexin A) in patients after repetitive generalized tonic-clonic seizures. Epilepsia. 2009; 50(6):1641-4. DOI: 10.1111/j.1528-1167.2008.01990.x. View

Sakamoto K, Saito T, Orman R, Koizumi K, Lazar J, Salciccioli L . Autonomic consequences of kainic acid-induced limbic cortical seizures in rats: peripheral autonomic nerve activity, acute cardiovascular changes, and death. Epilepsia. 2008; 49(6):982-96. DOI: 10.1111/j.1528-1167.2008.01545.x. View

Li Y, van den Pol A . Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides. J Neurosci. 2006; 26(50):13037-47. PMC: 6674960. DOI: 10.1523/JNEUROSCI.3380-06.2006. View

Kacinski M, Budziszewska B, Lason W, Zajac A, Skowronek-Bala B, Leskiewicz M . Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacol Rep. 2013; 64(6):1427-33. DOI: 10.1016/s1734-1140(12)70940-4. View

Saito T, Sakamoto K, Koizumi K, Stewart M . Repeatable focal seizure suppression: a rat preparation to study consequences of seizure activity based on urethane anesthesia and reversible carotid artery occlusion. J Neurosci Methods. 2006; 155(2):241-50. DOI: 10.1016/j.jneumeth.2006.01.021. View

Baracskay P, Kiglics V, Kekesi K, Juhasz G, Czurko A . Status epilepticus affects the gigantocellular network of the pontine reticular formation. BMC Neurosci. 2009; 10:133. PMC: 2781816. DOI: 10.1186/1471-2202-10-133. View

Hagan J, Leslie R, Patel S, Evans M, Wattam T, Holmes S . Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A. 1999; 96(19):10911-6. PMC: 17982. DOI: 10.1073/pnas.96.19.10911. View

Martin E, Pozo M . Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. Epilepsia. 2003; 44(11):1375-9. DOI: 10.1046/j.1528-1157.2003.11603.x. View

Cain D, Raithby A, Corcoran M . Urethane anesthesia blocks the development and expression of kindled seizures. Life Sci. 1989; 44(17):1201-6. DOI: 10.1016/0024-3205(89)90315-9. View

10.

Wahab A, Albus K, Gabriel S, Heinemann U . In search of models of pharmacoresistant epilepsy. Epilepsia. 2010; 51 Suppl 3:154-9. DOI: 10.1111/j.1528-1167.2010.02632.x. View

11.

Dias M, Li A, Nattie E . Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. J Physiol. 2009; 587(Pt 9):2059-67. PMC: 2689343. DOI: 10.1113/jphysiol.2008.168260. View

12.

Kukkonen J . Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol. 2012; 304(1):C2-32. DOI: 10.1152/ajpcell.00227.2012. View

13.

Rajasekaran K, Zanelli S, Goodkin H . Lessons from the laboratory: the pathophysiology, and consequences of status epilepticus. Semin Pediatr Neurol. 2010; 17(3):136-43. PMC: 2943667. DOI: 10.1016/j.spen.2010.06.002. View

14.

Thorpe A, Doane D, Sweet D, Beverly J, Kotz C . Orexin A in the rostrolateral hypothalamic area induces feeding by modulating GABAergic transmission. Brain Res. 2006; 1125(1):60-6. PMC: 1779580. DOI: 10.1016/j.brainres.2006.09.075. View

15.

Kilduff T, Peyron C . The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000; 23(8):359-65. DOI: 10.1016/s0166-2236(00)01594-0. View

16.

Zhang D, Bertram E . Suppressing limbic seizures by stimulating medial dorsal thalamic nucleus: factors for efficacy. Epilepsia. 2015; 56(3):479-88. DOI: 10.1111/epi.12916. View

17.

Yu W, Smith A, Pilitsis J, Shin D . Isovaline attenuates epileptiform activity and seizure behavior in 4-aminopyridine treated rats. Epilepsy Res. 2013; 108(2):331-5. DOI: 10.1016/j.eplepsyres.2013.11.020. View

18.

Kovacs A, Mihaly A, Komaromi A, Gyengesi E, Szente M, Weiczner R . Seizure, neurotransmitter release, and gene expression are closely related in the striatum of 4-aminopyridine-treated rats. Epilepsy Res. 2003; 55(1-2):117-29. DOI: 10.1016/s0920-1211(03)00113-x. View

19.

Smart D, Brough S, Jewitt F, Johns A, Porter R, Jerman J . SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol. 2001; 132(6):1179-82. PMC: 1572677. DOI: 10.1038/sj.bjp.0703953. View

20.

Stringer J . Amygdala stimulation produces two types of hippocampal afterdischarges in the urethane-anesthetized rat. Brain Res. 1992; 591(1):103-8. DOI: 10.1016/0006-8993(92)90983-g. View